Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the potential to deliver critical new insights.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.